Using synthetic nanoparticles to improve tuberculosis treatment by targeting immune cells
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
This study is looking at how tiny particles can help remove certain immune cells that make it harder for your body to fight tuberculosis, with the goal of making current TB treatments work better for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10923584 on NIH RePORTER |
What this research studies
This research investigates how synthetic nanoparticles can be used to deplete specific immune cells that suppress the body's ability to fight tuberculosis (TB). By understanding the role of myeloid-derived suppressor cells (MDSCs) in TB, the researchers aim to enhance the effectiveness of existing antibiotic treatments. The approach combines immunomodulatory therapies with traditional anti-TB antibiotics to improve patient outcomes. Patients may benefit from a more effective treatment strategy that addresses both the infection and the immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis who are experiencing challenges with current treatment methods.
Not a fit: Patients who do not have tuberculosis or those with advanced disease that is not responsive to treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with tuberculosis by enhancing the body's immune response.
How similar studies have performed: Previous research has shown promise in using immunomodulatory therapies in conjunction with antibiotics for other conditions, suggesting potential success for this novel approach in tuberculosis.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Rengarajan, Jyothi — Emory University
- Study coordinator: Rengarajan, Jyothi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.